ClinicalTrials.gg
Not yet recruitingNCT07943897PROTECTHER KITUpdated Nov 17, 2026

PROTECT-HER KIT to Improve HPV Self-Sampling Uptake Among Women in Selangor

An interventional study of PROTECT-HER KIT (Protection Motivation Theory-Based HPV Screening Education Kit) and Standard Ministry of Health (MOH) Educational Materials in Cervical Cancer Screening and Human Papillomavirus Infection, sponsored by Universiti Teknologi Mara. Not yet recruiting at 1 site in Malaysia. Open to female participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Universiti Teknologi Mara · Not applicable, Interventional, and Screening

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
30 Years to 65 Years
Sex
Female
01

Study summary

This study aims to evaluate the effectiveness of the Protection Motivation Theory-Based HPV Screening Education Kit (PROTECT-HER KIT) in improving human papillomavirus (HPV) self-sampling uptake among eligible women in KOSPEN communities in Selangor, Malaysia. The study uses a two-arm, parallel cluster randomised controlled trial involving 106 women aged 30-65 years across eight KOSPEN localities. Localities will be randomly allocated to receive either the PROTECT-HER KIT educational intervention or standard Ministry of Health educational materials. The primary outcome is HPV self-sampling uptake assessed at one and two months following the intervention. Secondary outcomes include cervical cancer awareness and protection motivation measured at baseline, one month, and two months.

Read the detailed description

The goal of this cluster randomised controlled trial is to evaluate the effectiveness of the Protection Motivation Theory-Based HPV Screening Education Kit (PROTECT-HER KIT) in improving human papillomavirus (HPV) self-sampling uptake, cervical cancer awareness, and protection motivation among eligible women in the Komuniti Sihat Pembina Negara (KOSPEN) communities in Selangor, Malaysia. The PROTECT-HER KIT is a newly developed health education package designed to improve women's knowledge, perceived risk, confidence, and motivation to undergo HPV self-sampling for cervical cancer screening.

The main questions this study aims to answer are:

Will the PROTECT-HER KIT increase HPV self-sampling uptake among eligible women in KOSPEN communities in Selangor?

Will the PROTECT-HER KIT improve cervical cancer awareness among participants?

Will the PROTECT-HER KIT improve protection motivation, including perceived severity, perceived vulnerability, response efficacy, self-efficacy, and perceived response costs related to HPV self-sampling?

To evaluate the effectiveness of the PROTECT-HER KIT, researchers will conduct a two-arm cluster randomised controlled trial involving eight KOSPEN localities in Selangor. The localities will be randomly assigned to either the intervention group or the control group. The intervention group will receive the PROTECT-HER KIT, comprising a structured face-to-face health education session using flipcharts, video demonstrations, facilitated discussions, and practical guidance on HPV self-sampling, followed by WhatsApp reinforcement messages and action-planning reminders. The control group will receive standard cervical cancer prevention educational materials from the Ministry of Health Malaysia.

Participants will:

Complete a baseline questionnaire (T0) assessing their sociodemographic characteristics, cervical cancer awareness, protection motivation, and previous cervical cancer screening history.

Receive either the PROTECT-HER KIT educational intervention or standard Ministry of Health educational materials, depending on the KOSPEN locality to which they belong.

Complete follow-up questionnaires at approximately one month (T1) and two months (T2) after the educational intervention to assess changes in cervical cancer awareness, protection motivation, and HPV self-sampling uptake.

Report whether they have undergone HPV self-sampling for cervical cancer screening during the follow-up period.

The findings will help determine whether a theory-based, community-delivered health education intervention can improve HPV self-sampling uptake and support cervical cancer prevention efforts in Malaysia.

02

Conditions studied

  • Cervical Cancer Screening
  • Human Papillomavirus Infection

Keywords

  • HPV Self-Sampling
  • Cervical Cancer Screening
  • Protection Motivation Theory
  • Health Education Intervention
  • Cluster Randomized Controlled Trial
03

In context

Papillomavirus Infections

580 studies on the registry are indexed under Papillomavirus Infections; 133 are open to participants now.

This study's planned enrollment of 106 is below the median of 229 across 404 interventional studies indexed under Papillomavirus Infections.

Browse Papillomavirus Infections studies →

Lead sponsor

Universiti Teknologi Mara is the lead sponsor of 27 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Malaysian women aged 30-65 years.
  2. Residing in a participating KOSPEN locality in Selangor.
  3. Able to read and understand Malay.
  4. Never screened or overdue for cervical cancer screening according to current Malaysian guidelines.
  5. Own a smartphone with WhatsApp.

Exclusion criteria

Exclusion Criteria:

  1. Physical or mental impairment preventing participation in study procedures.
  2. Declines to participate or provide .
  3. Diagnosed cervical cancer or precancerous cervical disease.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
106 participants (estimated)

Study arms

  • Experimental
    PROTECT-HER KIT

    Participants will receive a structured, approximately 90-minute face-to-face educational session incorporating four modules: cervical cancer and HPV risk education, HPV self-sampling procedures and skills, emotional and practical barriers, and action planning. Educational materials include flipcharts, video demonstrations, facilitated discussions and standardised WhatsApp reinforcement and reminders.

    Behavioral: PROTECT-HER KIT (Protection Motivation Theory-Based HPV Screening Education Kit)

  • Active comparator
    Standard Ministry of Health Education

    Participants will receive a one-off distribution of existing Ministry of Health educational materials containing general information on women's health and cervical cancer prevention. Participants will continue to have access to routine cervical cancer screening services.

    Behavioral: Standard Ministry of Health (MOH) Educational Materials

Interventions

  • BehavioralPROTECT-HER KIT (Protection Motivation Theory-Based HPV Screening Education Kit)

    Participants allocated to the intervention group will receive the PROTECT-HER KIT, a structured educational intervention based on Protection Motivation Theory (PMT) to improve cervical cancer awareness, protection motivation, and HPV self-sampling uptake. The intervention consists of a single approximately 90-minute, face-to-face small-group educational session delivered by the principal researcher using flipcharts, a video demonstration, facilitated discussions, and practical guidance on HPV self-sampling. The educational content addresses perceived severity, perceived vulnerability, response efficacy, self-efficacy, and perceived response costs related to cervical cancer screening. Standardised WhatsApp reinforcement messages and action-planning reminders will be provided following the session to encourage HPV self-sampling uptake. The intervention will be delivered after completion of the baseline assessment (T0).

  • BehavioralStandard Ministry of Health (MOH) Educational Materials

    Participants allocated to the control group will receive a one-off distribution of standard health educational materials sourced from the Ministry of Health Malaysia. These materials provide general information on women's health, cervical cancer prevention, and cervical cancer screening. Unlike the intervention group, participants will not receive the structured PROTECT-HER KIT educational session or standardised WhatsApp reinforcement messages. The educational materials will be distributed once following completion of the baseline assessment (T0). Participants will continue to have access to routine cervical cancer screening services.

06

What researchers measure

Primary outcomes

  1. Secondary: Cervical cancer awareness

    Cervical Cancer Awareness Scale (Cx-CAS), 15 items

    Time frame: Baseline, 1 and 2 months

Secondary outcomes

  1. Secondary: Cervical cancer awareness

    Cervical Cancer Awareness Scale (Cx-CAS), 15 items

    Time frame: Baseline, 1 and 2 months

  2. Secondary: Protection motivation

    Adapted Malay PMT questionnaire, 24 items

    Time frame: Baseline, 1 and 2 months

07

Study locations

1 site
  • Pejabat Kesihatan Daerah Petaling
    Petaling Jaya, Putrajaya 40000, Malaysia
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be made publicly available due to the sensitive nature of the information collected, including cervical cancer screening history, HPV self-sampling uptake, and health-related perceptions. Data confidentiality and participant privacy will be maintained in accordance with the approved study protocol, institutional ethical requirements, and applicable data protection regulations. Study findings will be disseminated through scientific publications and presentations in aggregate form without identifying individual participants.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2027; primary completion for Jun 2027, 3 months later.

Of 108 non-industry interventional studies with no phase under Papillomavirus Infections, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's planned 3 months is below that.

Counting every sponsor, half of 117 studies reached it within 26 months; a quarter within 11 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 17, 2026
StartEst.
Mar 1, 2027
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07943897
Lead sponsor
Universiti Teknologi Mara
Responsible party
Fairuz Alia Rafiai (Principal Investigator, Universiti Teknologi Mara) — Principal investigator
First posted
Nov 17, 2026
Start date
Mar 1, 2027 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

FAIRUZ ALIA RAFIAI
Contact
dr.fairuzalia@moh.gov.my
+60332584000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion